[New Year, New Weather!! D-innovation’s First Transfer-A API in 2024-Phloroglucinol/Phloroglucinol Trimethyl Ether]

A good start to the New Year! ! On January 11, 2024, Center for Drug Evaluation (CDE) of National Medical Products Administration registered our product 

phloroglucinol/phloroglucinol trimethyl ether as status A!!!

Phloroglucinol/phloroglucinol trimethyl ether can directly act on the smooth muscle of gastrointestinal tract and urogenital tract, and is a myotropic non-atropine and non-papaverine pure smooth muscle spasmolytic. It can be used for acute spasmodic pain caused by digestive system and biliary tract dysfunction; acute spasmodic urethral, bladder, renal colic; gynecological spasmodic pain. It is characterized by no anticholinergic effect and little side effect on cardiovascular system.

Basic information:

name: phloroglucinol     name: phloroglucinol trimethyl ether

Phloroglucinol 1,3,5-Trimethoxybenzene

CAS No.: 108-73-6   CAS No.: 621-23-8

Molecular formula: C6H6O3   Molecular formula: C9H12O3

Molecular weight: 126.11     Molecular weight: 168.19

Appearance: White to light white crystalline powder   Appearance: White crystalline powder

Melting range: 215 ℃ -220 ℃   Melting range: 50 ℃ -53 ℃

Approved Dosage Form:

1. Oral lyophilized tablets (80 mg/tablet)

2. Injection (4 mL: 40mg/tube)

3. Freeze-dried powder injection (40 mg/bottle)

PS: phloroglucinol/phloroglucinol trimethyl ether ratio of 1000:1

Project progress

Phloroglucinol, registration number: "Y20220000230", registration status: "A"

Phloroglucinol trimethyl ether, registration number: "Y20220000232", registration status: "A"

The core business of D-innovation

Related declaration service for generic APIs

R & D and large-scale production services of generic API intermediates

CMC Research Services for Innovative Drug Substances

CDMO services for innovative drug APIs and intermediates